BNP Paribas Financial Markets’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-20,503
| Closed | -$772K | – | 4159 |
|
|
2021
Q1 | $772K | Buy |
20,503
+15,657
| +323% | +$390K | ﹤0.01% | 2303 |
|
|
2020
Q4 | $82.4K | Sell |
4,846
-1,597
| -25% | -$20K | ﹤0.01% | 3312 |
|
|
2020
Q3 | $30.3K | Buy |
6,443
+5,529
| +605% | +$28.1K | ﹤0.01% | 3678 |
|
|
2020
Q2 | $5.58K | Sell |
914
-9,692
| -91% | -$39.9K | ﹤0.01% | 3963 |
|
|
2020
Q1 | $24.1K | Buy |
10,606
+2,311
| +28% | +$9.81K | ﹤0.01% | 3856 |
|
|
2019
Q4 | $38.1K | Buy |
8,295
+2,940
| +55% | +$11.6K | ﹤0.01% | 3792 |
|
|
2019
Q3 | $20.8K | Buy |
5,355
+1,646
| +44% | +$9.03K | ﹤0.01% | 3934 |
|
|
2019
Q2 | $22.4K | Sell |
3,709
-3,619
| -49% | -$34.6K | ﹤0.01% | 3856 |
|
|
2019
Q1 | $98.2K | Buy |
7,328
+6,967
| +1,930% | +$79.5K | ﹤0.01% | 3139 |
|
|
2018
Q4 | $3.36K | Sell |
361
-1,139
| -76% | -$13.6K | ﹤0.01% | 3699 |
|
|
2018
Q3 | $20.9K | Buy |
1,500
+72
| +5% | +$1.07K | ﹤0.01% | 3400 |
|
|
2018
Q2 | $22.6K | Sell |
1,428
-5,377
| -79% | -$93.8K | ﹤0.01% | 3450 |
|
|
2018
Q1 | $117K | Buy |
6,805
+1,155
| +20% | +$22.5K | ﹤0.01% | 3106 |
|
|
2017
Q4 | $124K | Buy |
5,650
+2,642
| +88% | +$85K | ﹤0.01% | 3194 |
|
|
2017
Q3 | $123K | Sell |
3,008
-219
| -7% | -$6.88K | ﹤0.01% | 2682 |
|
|
2017
Q2 | $97.2K | Sell |
3,227
-91
| -3% | -$2.84K | ﹤0.01% | 2840 |
|
|
2017
Q1 | $120K | Sell |
3,318
-1,810
| -35% | -$79.8K | ﹤0.01% | 2429 |
|
|
2016
Q4 | $257K | Buy |
5,128
+3,287
| +179% | +$173K | ﹤0.01% | 2057 |
|
|
2016
Q3 | $96.6K | Buy |
1,841
+787
| +75% | +$37.6K | ﹤0.01% | 2124 |
|
|
2016
Q2 | $43.6K | Buy |
+1,054
| New | +$45.8K | ﹤0.01% | 2339 |
|
|
2016
Q1 | – | Sell |
-4,742
| Closed | -$197K | – | 3260 |
|
|
2015
Q4 | $197K | Buy |
4,742
+358
| +8% | +$12K | ﹤0.01% | 1936 |
|
|
2015
Q3 | $67.5K | Sell |
4,384
-231,615
| -98% | -$4.98M | ﹤0.01% | 2647 |
|
|
2015
Q2 | $5.86M | Buy |
235,999
+235,652
| +67,911% | +$5.25M | 0.02% | 549 |
|
|
2015
Q1 | $7.93K | Buy |
+347
| New | +$8.76K | ﹤0.01% | 2880 |
|
|
2014
Q4 | – | Sell |
-1,066
| Closed | -$12.5K | – | 3509 |
|
|
2014
Q3 | $12.5K | Buy |
+1,066
| New | +$13.4K | ﹤0.01% | 3471 |
|
BNP Paribas Financial Markets's FPRX Position: Q2 2021 in Review
BNP Paribas Financial Markets sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 20,503 shares — an estimated $772K sold.
BNP Paribas Financial Markets first reported a position in FPRX in Q3 2014 and held it in 25 quarters. The position peaked at $5.86M in Q2 2015. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- BNP Paribas Financial Markets reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- BNP Paribas Financial Markets sold 20,503 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $772K.
- BNP Paribas Financial Markets first reported a position in Five Prime Therapeutics, Inc. in Q3 2014 and held it in 25 quarters.
- BNP Paribas Financial Markets's Five Prime Therapeutics, Inc. position peaked at $5.86M in Q2 2015.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2021, filed 10 Aug 2021.